Bladder Cancer Treatment Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:

Description

The global Bladder Cancer Treatment Drugs Market has exhibited remarkable growth, recording a valuation of US$ 4.1 billion in 2024. According to a recent study by Fairfield Market Research, this market is poised for rapid expansion over the next decade. By the end of 2031, the market is expected to reach an impressive US$ 13.3 billion.

The Two Faces of Bladder Cancer

Bladder cancer comes in two forms: non-muscle invasive bladder cancer, which affects only the bladder lining without penetrating deeper layers, and the more aggressive muscle-invasive bladder cancer, which invades the muscle layer of the bladder wall. Treatment options include chemotherapy, surgery, and radiotherapy.

Significant Market Share in Oncology

Bladder cancer treatment drugs, while representing only a 1.4% share of the global oncology drugs market in 2022, are on a trajectory of robust growth.

Key Opportunities for Drug Manufacturers

Advancing to Targeted Medications and Immunotherapies

The shift towards molecularly targeted medications and immunotherapies, as opposed to traditional chemotherapy, is gaining traction. Leading pharmaceutical companies like Bristol-Myers Squibb, Merck, and Roche have well-established immunotherapy portfolios, while AstraZeneca and Ferring B.V. are making significant strides in checkpoint-based immunotherapy approaches. This shift promises enhanced efficacy and improved quality of life for patients and is expected to represent 30% to 40% of the oncology medicines market in the next decade.

Challenges in Market Growth

High Development Costs and Limited Availability

The high cost and time-consuming nature of drug development, as well as a lack of innovation, pose challenges to the market. Furthermore, the availability of cancer medications is limited in underdeveloped and emerging nations, with only a handful of countries having access to a significant portion of these vital drugs.

Country-wise Insights

United States: High Spending on Cancer Treatment

The United States remains a substantial market for bladder cancer treatment drugs, primarily driven by the significant spending on cancer-related medical treatment. Projections indicate a considerable increase in cancer treatment spending in the coming years.

United Kingdom: Expanding Therapy Options

The United Kingdom's market for bladder cancer treatment drugs is expanding due to the availability of cutting-edge cancer therapies and a commitment to innovation in cancer treatments. The country has witnessed the approval of numerous novel treatments in recent years.

Competitive Landscape

The global market is characterized by consolidation, with a limited number of key players dominating. Key industry leaders are actively acquiring local competitors to expand their customer base and explore new markets.

Key Companies Profiled

Pfizer Inc.
Merck KgaA
Merck & Co
AstraZeneca PLC
Roche Holding AG (Genentech)
Astellas Pharma Inc.
J&J (Janssen Biotech)
Cipla Inc.
Amneal Pharma
Bristol Myers Squibb Co.
Dr. Reddy's Laboratories, Inc.
Gilead Sciences Inc.
Endo Pharma
UroGen Pharma, Inc.
Teva Pharmaceuticals (Actavis)
Hikma Pharmaceuticals, Incyte

Bladder Cancer Treatment Drugs Industry Research Segmentation

By Cancer Type:

Non-Muscle-Invasive Bladder Cancer
Muscle-Invasive Bladder Cancer

By Cancer Grade:

Low-Grade Bladder Cancer
High-Grade Bladder Cancer

By Drug Type:

Immunotherapy
- Bacillus Calmette-Guerin
- Avelumab
- Nivolumab
- Pembrolizumab
- Others

Chemotherapy
- Mitomycin C
- Docetaxel
- Paclitaxel
- Cisplatin
- Others

Targeted Therapy
- Erdafitinib
- Enfortumab vedotin-ejfv
- Sacituzumab govitecan
- Others

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Specialty Pharmacies
Online Pharmacies

By Region:

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East and Africa (MEA)

1. Executive Summary

1.1. Global Bladder Cancer Treatment Drugs Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Bladder Cancer Treatment Drugs Market Outlook, 2018 - 2031

3.1. Global Bladder Cancer Treatment Drugs Market Outlook, by Cancer Type, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Non-Muscle-Invasive Bladder Cancer
  - 3.1.1.2. Muscle-Invasive Bladder Cancer
3.2. Global Bladder Cancer Treatment Drugs Market Outlook, by Cancer Grade, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Low-Grade Bladder Cancer
  - 3.2.1.2. High-Grade Bladder Cancer
3.3. Global Bladder Cancer Treatment Drugs Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. Immunotherapy
    - 3.3.1.1.1. Bacillus Calmette-Guerin
    - 3.3.1.1.2. Avelumab
    - 3.3.1.1.3. Nivolumab
    - 3.3.1.1.4. Pembrolizumab
    - 3.3.1.1.5. Others
  - 3.3.1.2. Chemotherapy
    - 3.3.1.2.1. Mitomycin C
    - 3.3.1.2.2. Docetaxel
    - 3.3.1.2.3. Paclitaxel
    - 3.3.1.2.4. Cisplatin
    - 3.3.1.2.5. Others
  - 3.3.1.3. Targeted Therapy
    - 3.3.1.3.1. Erdafitinib
    - 3.3.1.3.2. Enfortumab vedotin-ejfv
    - 3.3.1.3.3. Sacituzumab govitecan
    - 3.3.1.3.4. Others
3.4. Global Bladder Cancer Treatment Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 3.4.1. Key Highlights
  - 3.4.1.1. Hospital Pharmacies
  - 3.4.1.2. Retail Pharmacies
  - 3.4.1.3. Specialty Pharmacies
  - 3.4.1.4. Online Pharmacies
3.5. Global Bladder Cancer Treatment Drugs Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.5.1. Key Highlights
  - 3.5.1.1. North America
  - 3.5.1.2. Europe
  - 3.5.1.3. Asia Pacific
  - 3.5.1.4. Latin America
  - 3.5.1.5. Middle East & Africa

4. North America Bladder Cancer Treatment Drugs Market Outlook, 2018 - 2031

4.1. North America Bladder Cancer Treatment Drugs Market Outlook, by Cancer Type, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Non-Muscle-Invasive Bladder Cancer
  - 4.1.1.2. Muscle-Invasive Bladder Cancer
4.2. North America Bladder Cancer Treatment Drugs Market Outlook, by Cancer Grade, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Low-Grade Bladder Cancer
  - 4.2.1.2. High-Grade Bladder Cancer
4.3. North America Bladder Cancer Treatment Drugs Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. Immunotherapy
    - 4.3.1.1.1. Bacillus Calmette-Guerin
    - 4.3.1.1.2. Avelumab
    - 4.3.1.1.3. Nivolumab
    - 4.3.1.1.4. Pembrolizumab
    - 4.3.1.1.5. Others
  - 4.3.1.2. Chemotherapy
    - 4.3.1.2.1. Mitomycin C
    - 4.3.1.2.2. Docetaxel
    - 4.3.1.2.3. Paclitaxel
    - 4.3.1.2.4. Cisplatin
    - 4.3.1.2.5. Others
  - 4.3.1.3. Targeted Therapy
    - 4.3.1.3.1. Erdafitinib
    - 4.3.1.3.2. Enfortumab vedotin-ejfv
    - 4.3.1.3.3. Sacituzumab govitecan
    - 4.3.1.3.4. Others
4.4. North America Bladder Cancer Treatment Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 4.4.1. Key Highlights
  - 4.4.1.1. Hospital Pharmacies
  - 4.4.1.2. Retail Pharmacies
  - 4.4.1.3. Specialty Pharmacies
  - 4.4.1.4. Online Pharmacies
4.5. North America Bladder Cancer Treatment Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.5.1. Key Highlights
  - 4.5.1.1. U.S. Bladder Cancer Treatment Drugs Market by Cancer Type, Value (US$ Bn), 2018 - 2031
  - 4.5.1.2. U.S. Bladder Cancer Treatment Drugs Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
  - 4.5.1.3. U.S. Bladder Cancer Treatment Drugs Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 4.5.1.4. U.S. Bladder Cancer Treatment Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 4.5.1.5. Canada Bladder Cancer Treatment Drugs Market by Cancer Type, Value (US$ Bn), 2018 - 2031
  - 4.5.1.6. Canada Bladder Cancer Treatment Drugs Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
  - 4.5.1.7. Canada Bladder Cancer Treatment Drugs Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 4.5.1.8. Canada Bladder Cancer Treatment Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Bladder Cancer Treatment Drugs Market Outlook, 2018 - 2031

5.1. Europe Bladder Cancer Treatment Drugs Market Outlook, by Cancer Type, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Non-Muscle-Invasive Bladder Cancer
  - 5.1.1.2. Muscle-Invasive Bladder Cancer
5.2. Europe Bladder Cancer Treatment Drugs Market Outlook, by Cancer Grade, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Low-Grade Bladder Cancer
  - 5.2.1.2. High-Grade Bladder Cancer
5.3. Europe Bladder Cancer Treatment Drugs Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Immunotherapy
    - 5.3.1.1.1. Bacillus Calmette-Guerin
    - 5.3.1.1.2. Avelumab
    - 5.3.1.1.3. Nivolumab
    - 5.3.1.1.4. Pembrolizumab
    - 5.3.1.1.5. Others
  - 5.3.1.2. Chemotherapy
    - 5.3.1.2.1. Mitomycin C
    - 5.3.1.2.2. Docetaxel
    - 5.3.1.2.3. Paclitaxel
    - 5.3.1.2.4. Cisplatin
    - 5.3.1.2.5. Others
  - 5.3.1.3. Targeted Therapy
    - 5.3.1.3.1. Erdafitinib
    - 5.3.1.3.2. Enfortumab vedotin-ejfv
    - 5.3.1.3.3. Sacituzumab govitecan
    - 5.3.1.3.4. Others
5.4. Europe Bladder Cancer Treatment Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 5.4.1. Key Highlights
  - 5.4.1.1. Hospital Pharmacies
  - 5.4.1.2. Retail Pharmacies
  - 5.4.1.3. Specialty Pharmacies
  - 5.4.1.4. Online Pharmacies
5.5. Europe Bladder Cancer Treatment Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.5.1. Key Highlights
  - 5.5.1.1. Germany Bladder Cancer Treatment Drugs Market by Cancer Type, Value (US$ Bn), 2018 - 2031
  - 5.5.1.2. Germany Bladder Cancer Treatment Drugs Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
  - 5.5.1.3. Germany Bladder Cancer Treatment Drugs Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 5.5.1.4. Germany Bladder Cancer Treatment Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.5.1.5. U.K. Bladder Cancer Treatment Drugs Market by Cancer Type, Value (US$ Bn), 2018 - 2031
  - 5.5.1.6. U.K. Bladder Cancer Treatment Drugs Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
  - 5.5.1.7. U.K. Bladder Cancer Treatment Drugs Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 5.5.1.8. U.K. Bladder Cancer Treatment Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.5.1.9. France Bladder Cancer Treatment Drugs Market by Cancer Type, Value (US$ Bn), 2018 - 2031
  - 5.5.1.10. France Bladder Cancer Treatment Drugs Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
  - 5.5.1.11. France Bladder Cancer Treatment Drugs Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 5.5.1.12. France Bladder Cancer Treatment Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.5.1.13. Italy Bladder Cancer Treatment Drugs Market by Cancer Type, Value (US$ Bn), 2018 - 2031
  - 5.5.1.14. Italy Bladder Cancer Treatment Drugs Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
  - 5.5.1.15. Italy Bladder Cancer Treatment Drugs Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 5.5.1.16. Italy Bladder Cancer Treatment Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.5.1.17. Turkey Bladder Cancer Treatment Drugs Market by Cancer Type, Value (US$ Bn), 2018 - 2031
  - 5.5.1.18. Turkey Bladder Cancer Treatment Drugs Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
  - 5.5.1.19. Turkey Bladder Cancer Treatment Drugs Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 5.5.1.20. Turkey Bladder Cancer Treatment Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.5.1.21. Russia Bladder Cancer Treatment Drugs Market by Cancer Type, Value (US$ Bn), 2018 - 2031
  - 5.5.1.22. Russia Bladder Cancer Treatment Drugs Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
  - 5.5.1.23. Russia Bladder Cancer Treatment Drugs Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 5.5.1.24. Russia Bladder Cancer Treatment Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.5.1.25. Rest of Europe Bladder Cancer Treatment Drugs Market by Cancer Type, Value (US$ Bn), 2018 - 2031
  - 5.5.1.26. Rest of Europe Bladder Cancer Treatment Drugs Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
  - 5.5.1.27. Rest of Europe Bladder Cancer Treatment Drugs Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 5.5.1.28. Rest of Europe Bladder Cancer Treatment Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Bladder Cancer Treatment Drugs Market Outlook, 2018 - 2031

6.1. Asia Pacific Bladder Cancer Treatment Drugs Market Outlook, by Cancer Type, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Non-Muscle-Invasive Bladder Cancer
  - 6.1.1.2. Muscle-Invasive Bladder Cancer
6.2. Asia Pacific Bladder Cancer Treatment Drugs Market Outlook, by Cancer Grade, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Low-Grade Bladder Cancer
  - 6.2.1.2. High-Grade Bladder Cancer
6.3. Asia Pacific Bladder Cancer Treatment Drugs Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. Immunotherapy
    - 6.3.1.1.1. Bacillus Calmette-Guerin
    - 6.3.1.1.2. Avelumab
    - 6.3.1.1.3. Nivolumab
    - 6.3.1.1.4. Pembrolizumab
    - 6.3.1.1.5. Others
  - 6.3.1.2. Chemotherapy
    - 6.3.1.2.1. Mitomycin C
    - 6.3.1.2.2. Docetaxel
    - 6.3.1.2.3. Paclitaxel
    - 6.3.1.2.4. Cisplatin
    - 6.3.1.2.5. Others
  - 6.3.1.3. Targeted Therapy
    - 6.3.1.3.1. Erdafitinib
    - 6.3.1.3.2. Enfortumab vedotin-ejfv
    - 6.3.1.3.3. Sacituzumab govitecan
    - 6.3.1.3.4. Others
6.4. Asia Pacific Bladder Cancer Treatment Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 6.4.1. Key Highlights
  - 6.4.1.1. Hospital Pharmacies
  - 6.4.1.2. Retail Pharmacies
  - 6.4.1.3. Specialty Pharmacies
  - 6.4.1.4. Online Pharmacies
6.5. Asia Pacific Bladder Cancer Treatment Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.5.1. Key Highlights
  - 6.5.1.1. China Bladder Cancer Treatment Drugs Market by Cancer Type, Value (US$ Bn), 2018 - 2031
  - 6.5.1.2. China Bladder Cancer Treatment Drugs Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
  - 6.5.1.3. China Bladder Cancer Treatment Drugs Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 6.5.1.4. China Bladder Cancer Treatment Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.5.1.5. Japan Bladder Cancer Treatment Drugs Market by Cancer Type, Value (US$ Bn), 2018 - 2031
  - 6.5.1.6. Japan Bladder Cancer Treatment Drugs Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
  - 6.5.1.7. Japan Bladder Cancer Treatment Drugs Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 6.5.1.8. Japan Bladder Cancer Treatment Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.5.1.9. South Korea Bladder Cancer Treatment Drugs Market by Cancer Type, Value (US$ Bn), 2018 - 2031
  - 6.5.1.10. South Korea Bladder Cancer Treatment Drugs Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
  - 6.5.1.11. South Korea Bladder Cancer Treatment Drugs Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 6.5.1.12. South Korea Bladder Cancer Treatment Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.5.1.13. India Bladder Cancer Treatment Drugs Market by Cancer Type, Value (US$ Bn), 2018 - 2031
  - 6.5.1.14. India Bladder Cancer Treatment Drugs Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
  - 6.5.1.15. India Bladder Cancer Treatment Drugs Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 6.5.1.16. India Bladder Cancer Treatment Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.5.1.17. Southeast Asia Bladder Cancer Treatment Drugs Market by Cancer Type, Value (US$ Bn), 2018 - 2031
  - 6.5.1.18. Southeast Asia Bladder Cancer Treatment Drugs Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
  - 6.5.1.19. Southeast Asia Bladder Cancer Treatment Drugs Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 6.5.1.20. Southeast Asia Bladder Cancer Treatment Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.5.1.21. Rest of Asia Pacific Bladder Cancer Treatment Drugs Market by Cancer Type, Value (US$ Bn), 2018 - 2031
  - 6.5.1.22. Rest of Asia Pacific Bladder Cancer Treatment Drugs Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
  - 6.5.1.23. Rest of Asia Pacific Bladder Cancer Treatment Drugs Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 6.5.1.24. Rest of Asia Pacific Bladder Cancer Treatment Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Bladder Cancer Treatment Drugs Market Outlook, 2018 - 2031

7.1. Latin America Bladder Cancer Treatment Drugs Market Outlook, by Cancer Type, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Non-Muscle-Invasive Bladder Cancer
  - 7.1.1.2. Muscle-Invasive Bladder Cancer
7.2. Latin America Bladder Cancer Treatment Drugs Market Outlook, by Cancer Grade, Value (US$ Bn), 2018 - 2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Low-Grade Bladder Cancer
  - 7.2.1.2. High-Grade Bladder Cancer
7.3. Latin America Bladder Cancer Treatment Drugs Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Immunotherapy
    - 7.3.1.1.1. Bacillus Calmette-Guerin
    - 7.3.1.1.2. Avelumab
    - 7.3.1.1.3. Nivolumab
    - 7.3.1.1.4. Pembrolizumab
    - 7.3.1.1.5. Others
  - 7.3.1.2. Chemotherapy
    - 7.3.1.2.1. Mitomycin C
    - 7.3.1.2.2. Docetaxel
    - 7.3.1.2.3. Paclitaxel
    - 7.3.1.2.4. Cisplatin
    - 7.3.1.2.5. Others
  - 7.3.1.3. Targeted Therapy
    - 7.3.1.3.1. Erdafitinib
    - 7.3.1.3.2. Enfortumab vedotin-ejfv
    - 7.3.1.3.3. Sacituzumab govitecan
    - 7.3.1.3.4. Others
7.4. Latin America Bladder Cancer Treatment Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 7.4.1. Key Highlights
  - 7.4.1.1. Hospital Pharmacies
  - 7.4.1.2. Retail Pharmacies
  - 7.4.1.3. Specialty Pharmacies
  - 7.4.1.4. Online Pharmacies
7.5. Latin America Bladder Cancer Treatment Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.5.1. Key Highlights
  - 7.5.1.1. Brazil Bladder Cancer Treatment Drugs Market by Cancer Type, Value (US$ Bn), 2018 - 2031
  - 7.5.1.2. Brazil Bladder Cancer Treatment Drugs Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
  - 7.5.1.3. Brazil Bladder Cancer Treatment Drugs Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 7.5.1.4. Brazil Bladder Cancer Treatment Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.5.1.5. Mexico Bladder Cancer Treatment Drugs Market by Cancer Type, Value (US$ Bn), 2018 - 2031
  - 7.5.1.6. Mexico Bladder Cancer Treatment Drugs Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
  - 7.5.1.7. Mexico Bladder Cancer Treatment Drugs Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 7.5.1.8. Mexico Bladder Cancer Treatment Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.5.1.9. Argentina Bladder Cancer Treatment Drugs Market by Cancer Type, Value (US$ Bn), 2018 - 2031
  - 7.5.1.10. Argentina Bladder Cancer Treatment Drugs Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
  - 7.5.1.11. Argentina Bladder Cancer Treatment Drugs Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 7.5.1.12. Argentina Bladder Cancer Treatment Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.5.1.13. Rest of Latin America Bladder Cancer Treatment Drugs Market by Cancer Type, Value (US$ Bn), 2018 - 2031
  - 7.5.1.14. Rest of Latin America Bladder Cancer Treatment Drugs Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
  - 7.5.1.15. Rest of Latin America Bladder Cancer Treatment Drugs Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 7.5.1.16. Rest of Latin America Bladder Cancer Treatment Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Bladder Cancer Treatment Drugs Market Outlook, 2018 - 2031

8.1. Middle East & Africa Bladder Cancer Treatment Drugs Market Outlook, by Cancer Type, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Non-Muscle-Invasive Bladder Cancer
  - 8.1.1.2. Muscle-Invasive Bladder Cancer
8.2. Middle East & Africa Bladder Cancer Treatment Drugs Market Outlook, by Cancer Grade, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Low-Grade Bladder Cancer
  - 8.2.1.2. High-Grade Bladder Cancer
8.3. Middle East & Africa Bladder Cancer Treatment Drugs Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. Immunotherapy
    - 8.3.1.1.1. Bacillus Calmette-Guerin
    - 8.3.1.1.2. Avelumab
    - 8.3.1.1.3. Nivolumab
    - 8.3.1.1.4. Pembrolizumab
    - 8.3.1.1.5. Others
  - 8.3.1.2. Chemotherapy
    - 8.3.1.2.1. Mitomycin C
    - 8.3.1.2.2. Docetaxel
    - 8.3.1.2.3. Paclitaxel
    - 8.3.1.2.4. Cisplatin
    - 8.3.1.2.5. Others
  - 8.3.1.3. Targeted Therapy
    - 8.3.1.3.1. Erdafitinib
    - 8.3.1.3.2. Enfortumab vedotin-ejfv
    - 8.3.1.3.3. Sacituzumab govitecan
    - 8.3.1.3.4. Others
8.4. Middle East & Africa Bladder Cancer Treatment Drugs Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 8.4.1. Key Highlights
  - 8.4.1.1. Hospital Pharmacies
  - 8.4.1.2. Retail Pharmacies
  - 8.4.1.3. Specialty Pharmacies
  - 8.4.1.4. Online Pharmacies
8.5. Middle East & Africa Bladder Cancer Treatment Drugs Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.5.1. Key Highlights
  - 8.5.1.1. GCC Bladder Cancer Treatment Drugs Market by Cancer Type, Value (US$ Bn), 2018 - 2031
  - 8.5.1.2. GCC Bladder Cancer Treatment Drugs Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
  - 8.5.1.3. GCC Bladder Cancer Treatment Drugs Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 8.5.1.4. GCC Bladder Cancer Treatment Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.5.1.5. South Africa Bladder Cancer Treatment Drugs Market by Cancer Type, Value (US$ Bn), 2018 - 2031
  - 8.5.1.6. South Africa Bladder Cancer Treatment Drugs Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
  - 8.5.1.7. South Africa Bladder Cancer Treatment Drugs Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 8.5.1.8. South Africa Bladder Cancer Treatment Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.5.1.9. Egypt Bladder Cancer Treatment Drugs Market by Cancer Type, Value (US$ Bn), 2018 - 2031
  - 8.5.1.10. Egypt Bladder Cancer Treatment Drugs Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
  - 8.5.1.11. Egypt Bladder Cancer Treatment Drugs Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 8.5.1.12. Egypt Bladder Cancer Treatment Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.5.1.13. Nigeria Bladder Cancer Treatment Drugs Market by Cancer Type, Value (US$ Bn), 2018 - 2031
  - 8.5.1.14. Nigeria Bladder Cancer Treatment Drugs Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
  - 8.5.1.15. Nigeria Bladder Cancer Treatment Drugs Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 8.5.1.16. Nigeria Bladder Cancer Treatment Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.5.1.17. Rest of Middle East & Africa Bladder Cancer Treatment Drugs Market by Cancer Type, Value (US$ Bn), 2018 - 2031
  - 8.5.1.18. Rest of Middle East & Africa Bladder Cancer Treatment Drugs Market by Cancer Grade, Value (US$ Bn), 2018 - 2031
  - 8.5.1.19. Rest of Middle East & Africa Bladder Cancer Treatment Drugs Market by Drug Type, Value (US$ Bn), 2018 - 2031
  - 8.5.1.20. Rest of Middle East & Africa Bladder Cancer Treatment Drugs Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Cancer Type vs Cancer Grade Heatmap
9.2. Manufacturer vs Indication Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
- 9.5.1. Pfizer Inc.
  - 9.5.1.1. Company Overview
  - 9.5.1.2. Product Portfolio
  - 9.5.1.3. Financial Overview
  - 9.5.1.4. Business Strategies and Development
- 9.5.2. Merck KgaA
  - 9.5.2.1. Company Overview
  - 9.5.2.2. Product Portfolio
  - 9.5.2.3. Financial Overview
  - 9.5.2.4. Business Strategies and Development
- 9.5.3. Merck & Co
  - 9.5.3.1. Company Overview
  - 9.5.3.2. Product Portfolio
  - 9.5.3.3. Financial Overview
  - 9.5.3.4. Business Strategies and Development
- 9.5.4. AstraZeneca PLC
  - 9.5.4.1. Company Overview
  - 9.5.4.2. Product Portfolio
  - 9.5.4.3. Financial Overview
  - 9.5.4.4. Business Strategies and Development
- 9.5.5. Roche Holding AG (Genentech)
  - 9.5.5.1. Company Overview
  - 9.5.5.2. Product Portfolio
  - 9.5.5.3. Financial Overview
  - 9.5.5.4. Business Strategies and Development
- 9.5.6. Astellas Pharma Inc.
  - 9.5.6.1. Company Overview
  - 9.5.6.2. Product Portfolio
  - 9.5.6.3. Financial Overview
  - 9.5.6.4. Business Strategies and Development
- 9.5.7. J&J (Janssen Biotech)
  - 9.5.7.1. Company Overview
  - 9.5.7.2. Product Portfolio
  - 9.5.7.3. Financial Overview
  - 9.5.7.4. Business Strategies and Development
- 9.5.8. Cipla Inc.
  - 9.5.8.1. Company Overview
  - 9.5.8.2. Product Portfolio
  - 9.5.8.3. Financial Overview
  - 9.5.8.4. Business Strategies and Development
- 9.5.9. Amneal Pharma,
  - 9.5.9.1. Company Overview
  - 9.5.9.2. Product Portfolio
  - 9.5.9.3. Financial Overview
  - 9.5.9.4. Business Strategies and Development
- 9.5.10. Bristol Myers Squibb Co.
  - 9.5.10.1. Company Overview
  - 9.5.10.2. Product Portfolio
  - 9.5.10.3. Financial Overview
  - 9.5.10.4. Business Strategies and Development
- 9.5.11. Dr Reddy's Laboratories, Inc.
  - 9.5.11.1. Company Overview
  - 9.5.11.2. Product Portfolio
  - 9.5.11.3. Financial Overview
  - 9.5.11.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations